Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
about
Roflumilast: a review of its use in the treatment of COPDRising Costs of COPD and the Potential for Maintenance Therapy to Slow the TrendSystematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and RecommendationsUsing Big Data to Assess Prescribing Patterns in Greece: The Case of Chronic Obstructive Pulmonary Disease.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Vulnerable COPD patients with comorbidities: the role of roflumilast.Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD.Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.COPD management costs according to the frequency of COPD exacerbations in UK primary care.Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.Cost-effectiveness of pharmacotherapy for COPD in ambulatory care: a review.Roflumilast: A Review in COPD.Resource Use and Costs up to Two Years Post Diagnosis Among Newly Diagnosed COPD Patients in the UK Primary Care Setting: A Retrospective Cohort Study.Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
P2860
Q26770501-A4DA4465-7151-4F4B-B4E9-C38A425D5860Q27026708-708C3128-6D90-4C49-8F01-D548045F81E0Q30245662-3F785C77-1438-40E1-B081-30AE58212C18Q31097021-8226E49E-8D8A-4C2B-A8A5-50FAE173B739Q34065276-5F4AEA56-995F-4D6F-826A-05EE379184B0Q34566361-6278FD4C-42BC-4E9F-8D29-932BCDF8ADE2Q35194591-810865EF-AE41-4EFB-AE0C-C28A048F8129Q36584673-955BD7AC-7C35-46E6-A199-A81A5149A701Q37409751-F0E9E9D9-F4B8-4498-81CE-FE594E9F46BCQ37470650-17A19D7B-A8F0-4BAE-A520-A1C40DE5081CQ37473344-F5175E07-54EB-4C73-BCF2-4DE36F5CC1A8Q38063794-B08BF0C8-BBF3-46C6-A171-0E3D12497B79Q38099359-2EAC6CC3-843D-48B5-9EB2-0F36FD4CA742Q38580536-9DF79372-49BE-4262-96D4-684C3963F4A7Q44362260-82E26E00-D91D-49F7-939E-4B4CB0EE7682Q47138380-5B05DCF6-0E20-42D2-8DAA-E6759E648544
P2860
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cost-effectiveness of availabl ...... a fully incremental analysis.
@ast
Cost-effectiveness of availabl ...... a fully incremental analysis.
@en
type
label
Cost-effectiveness of availabl ...... a fully incremental analysis.
@ast
Cost-effectiveness of availabl ...... a fully incremental analysis.
@en
prefLabel
Cost-effectiveness of availabl ...... a fully incremental analysis.
@ast
Cost-effectiveness of availabl ...... a fully incremental analysis.
@en
P2093
P2860
P356
P1476
Cost-effectiveness of availabl ...... : a fully incremental analysis
@en
P2093
Kevin Jameson
Matthew Radford
Nadine Hertel
Robert W Kotchie
Samantha Humphreys
P2860
P304
P356
10.2147/COPD.S29820
P407
P577
2012-03-19T00:00:00Z